The involvement of the lymphocyte function-associated antigen-1 (LFA-1) membrane molecule in cytolytic T lymphocyte (CTL) interactions with lymphoid target cells was investigated using CTL clones derived from two patients with a heritable deficiency of LFA-1. LFA-1 surface expression on the CTL clones was 1% of the normal level of LFA-1, unchanged with prolonged culture, and identical on 14 different CTL clones. The function of the LFA-1 molecule was addressed using the LFA-1-deficient CTL clones and LFA-1-deficient lymphoid target cells. The lytic activity of the LFA-1-deficient CTL clones was 43% of control when tested against a target cell line expressing normal levels of LFA-1 and <10% of control when tested against an LFA-1-deficient target cell line. These results demonstrate a direct involvement of LFA-1 in CTL-mediated cytolysis and suggest a more general dependence on LFA-1 in lymphoid cell-cell interactions.
Introduction
Human lymphocyte function-associated antigen-1 (LFA-1)' is a 177-and 95-kD glycoprotein heterodimer that is expressed on all leukocytes, most thymocytes, and on a third ofbone marrow cells (1) . The LFA-l molecule was initially identified by screening monoclonal antibodies (MAb) for their ability to inhibit cytolytic T lymphocyte (CTL)-mediated cytotoxicity in the absence of complement (1, 2) . MAb to LFA-l significantly inhibited not only cell-mediated cytotoxicity but T cell proliferation as well (1) . In contrast, MAb to a variety ofother cell surface molecules, often present at higher cell surface density than LFA-1, did not inhibit T cell function. The ability of anti-LFA-1 MAb to inhibit a variety of T cell functions led to the suggestion that LFA-l was an essential cell-cell interaction molecule.
A unique opportunity to assess the function of the LFA-l molecule has been provided by patients with a genetic deficiency of the LFA-I glycoprotein. The LFA-I deficiency syndrome is an immunodeficiency characterized by a susceptibility to re-1. Abbreviations used in this paper: CR3, complement receptor type 3; CTL, cytolytic T lymphocyte; EBV, Epstein-Barr virus; F-GAM, fluorescein-conjugated F(ab')2 goat anti-mouse antibody; IL-2, interleukin 2; LFA-1, lymphocyte function-associated antigen-l; LU, lytic units; MAb, monoclonal antibodies. current life-threatening infections (3) . Biochemical analysis of the leukocytes from LFA-I -deficient patients have shown a deficiency of not only LFA-1, but of a structurally related family of molecules (4) . LFA-1, complement receptor type 3 (CR3), and p1 50,95 are heterodimers with different heavy chains but a structurally identical 95-kD light chain. All three molecules are deficient in patients with the clinical syndrome (5) . The advantage of studying CTL from these deficient patients is that significant levels of CR3 and p 150,95 are not expressed on normal T cells. Thus, the CTL from these patients have a selective deficiency of the LFA-1 membrane molecule.
Previous in vitro studies of LFA-1-deficient CTL function have been inconclusive. Arnaout (10) . Therefore, a comparison of clones directed at the same alloantigen should provide a more definitive evaluation of cytolytic activity.
In this report, we used the genetic deficiency of LFA-l to investigate the role of LFA-l in CTL-target cell interactions. U/ml penicillin (Gibco), 100 ,g/ml streptomycin (Gibco), 10 Interleukin 2 (IL-2) containing human conditioned medium. The method for IL-2 production has been described elsewhere (10) . Briefly, peripheral blood leukocytes obtained from five different platelet donors were mixed and washed three times. The cells were resuspended at a concentration of 3 X 10' cells/ml in RPMI 1640 (M. A. Bioproducts) containing 3% fetal calf serum and 0.15% phytohemagglutinin (Bacto PHA-P; Difco Laboratories, Detroit, MI). Special additives included 2.8 ,gM indomethacin, 3 mM lithium chloride, and 50 ,M hydroxyurea, all from Sigma Chemical Co. The cells were cultured for 72 h and the supernatants were collected. The supernatants were ammonium sulfateprecipitated (50%, 75%) and dialyzed. The purified conditioned medium was filter sterilized and stored at -40C.
Cytotoxicity assay. CTL assays were performed in triplicate in Vbottom microtiter wells (Linbro, Flow Laboratories, Hamden, CT). Effector cells were added in threefold dilutions. Target cells, preincubated in 0.1 mCi of5"Cr (Na5lCrO4, New England Nuclear, Boston, MA) for 2 h and washed three times, were added at 103 cells/well. Microtiter plates were centrifuged and incubated at 370C for 4 h. After incubation, the plates were again centrifuged and the supernatants assayed for 51Cr-release. Specific cytotoxicity was calculated as percent cytotoxicity = 100 X (cpm experimental release -cpm spontaneous release)/(total cpm -cpm spontaneous release). When blocking monoclonal antibodies were used, they were added to the wells at the start of the assay. The standard deviation ofthe triplicate wells rarely exceeded 2-4% of the specific lysis. Lytic units (LU) were calculated as the number of effector cells required for 50% lysis of I03 target cells. LU were based on effector titrations and confirmed with the following formula: LU/l0' = I0'/(effector cells/target cells) X [(plateau cpm -sample cpm)/(cpm sample)].
CTL clones. Peripheral blood mononuclear cells were separated on a Ficoll/Hypaque gradient (Lymphocyte Separation Medium, Bionetics, Kensington, MD). The mononuclear cells at 2 X 106 cells/ml were cocultured with irradiated JY at I X 105 cells/ml in 2-ml wells (Linbro) at 370C in a 5% CO2 incubator. The bulk culture was maintained in 9.6-cm2 wells (Nunc, Vangard, Neptune, NJ) by stimulation every 1-2 wk with irradiated stimulator cells. After 6 wk in culture, the cells were again isolated using a Ficoll-Hypaque gradient and cloned using limiting dilution in 96-well round-bottom microtiter plates (Linbro) with 2 X 104 irradiated JY cells as a feeder layer. Culture medium containing 10% human conditioned medium was used for cloning; fresh medium was added every 3 d. Clones were obtained at a concentration of 1 celi/10 wells. The clones chosen for further analysis were subcloned at <1 cell/ well. The specificity ofeach clone was determined using a panel of HLAtyped target cells and monoclonal antibody blocking. Col clones 350, 349, and 354 were specific for HLA-A2; clones 147, 303, and 353 were specific for HLA-B7. The CTL line MMJ was specific for the cell line JY. These clones were shown to have comparable lytic activity in comparisons with clones obtained from two other normal donors.
Cell surface immunofluorescence. Cells were washed twice with phosphate-buffered saline containing 2.5% fetal calf serum and 0.02% sodium azide. Approximately 106 cells were incubated on ice for 30 min with an excess concentration of monoclonal antibody. The cells were washed twice and stained with fluorescein-conjugated goat F(ab')2-antimouse (F-GAM) IgG antibody (Tago Inc., Burlingame, CA) diluted 1:10. The cells were incubated on ice for another 30 min. After three washes, the cells were fixed in 1% paraformaldehyde and analyzed on a FACS I (Becton-Dickinson & Co., Mountain View, CA).
Monoclonal antibodies. MAbto LFA-l were derived from subcloned hybridomas that produced antibodies to LFA-l as previously described (2) . MAb to the LFA-l alpha chain were TS1/22, TS2/14, TSl/l 1, and TS2/4. MAb to the LFA-l beta chain was TSI/18. Titration curves were used to establish saturating concentrations of MAb. The HLA-A2-specific MAb PA2. 1 was described elsewhere (11) .
Tumor cell lines. The human tumor cell lines were maintained in culture media and regularly passaged. Fig. 1 . Surface expression of LFA-I on the CTL clones was also the same level as on the bulk CTL population. Thus, no heterogeneity of LFA-l surface expression was observed on the LFA-l-deficient CTL.
Lytic activity of LFA-J-deficient CTL clones. The genetic deficiency of LFA-1 permitted the assessment of CTL interactions with lymphoid target cells when LFA-1 was (a) deficient on the CTL, (b) deficient on the target cell, or (c) deficient on both the CTL and target cell. In normal circumstances, LFA-I is present on all lymphocytes. Although LFA-I is expressed on both CTL and lymphoid target cells, the CTL-target cell interaction appears to depend primarily on the LFA-l expressed on the CTL. MAb pretreatment of the effector cell maximally inhibits cytolysis, whereas MAb pretreatment of the target cell has minimal effect (1). Despite the significant deficiency of LFA-1, detailed analysis of six HLA-A2-specific CTL clones showed that the LFA-l-deficient clones were capable of effectively lysing a variety of lymphoid target cells (Table I ). Based on 26 separate experiments, the lytic activity ofthe LFA-l-deficient CTL clones (as quantified by lytic units) was 43% of control CTL clones (Table II) .
The effective lysis of lymphoid target cells suggested that LFA-l-deficient CTL could compensate for their deficiency. The molecular basis for this compensation was unclear. The LFA-1-deficient CTL clones did not express an increased number of antigen nonspecific or "accessory" molecules that have been shown to participate in the CTL-target cell interaction. The (Table III) . CTL clones specific for HLA-A2 were tested for lytic activity against JY and the LFA-l-deficient target cell BBN. Calculation of LU indicated that the lytic activity on the LFA-l-deficient target BBN by the LFA-l-deficient CTL clones was <10% of CTL clones expressing normal levels of LFA-1 (Table IV) . This significant decrease in lytic activity was found with all LFA-1-deficient clones tested. Utilization of the LFA-i molecule. The diminished ability to lyse LFA-l-deficient target cells demonstrated that LFA-l- (Table V) .
Discussion
The genetic deficiency of the LFA-l membrane glycoprotein has provided a unique opportunity to assess the direct involvement of this molecule in CTL function. Six HLA-A2-specific CTL clones from two patients with a deficiency of LFA-I demonstrated abnormal cytolytic function. The cytolytic activity of these CTL clones was <50% of the lytic activity of control CTL clones. When LFA-1 expression was deficient on both the CTL and the target cell, lytic activity was <10% of control. These The variance of lytic activity between experiments was always <10%.
§ Lytic activity of control and LFA-l-deficient CTL were significantly different, P < 0.01, as assessed by the Wilcoxon rank sum test.
Lymphocyte Function-associated Antigen-I Deficiency 1389 (6, 7, 9) . These observations, as well as normal serum immunoglobulin levels and relatively normal delayed hypersensitivity reactions, have led to the speculation that granulocyte function is more impaired than T cell function. Only two reported LFA-lI-deficient patients have developed significant infectious complications attributable to a cell-mediated immune defect. One patient died of overwhelming picornavirus infection of the tracheobronchial tree (3) . The other patient developed cutaneous candidiasis (9) .
The failure of most LFA-lI-deficient patients to manifest a clinically significant T cell defect suggests that T cells compensate for their deficiency. There are a number of potential mechanisms of CTL compensation. The most important mechanism is that T cells, in contrast to granulocytes, respond to antigenic challenge by clonal expansion. Studies of polyclonal populations of LFA-1-deficient CTL suggest that antigenic challenge expands those T cells with the greatest capacity to proliferate and exhibit cytolytic activity. The molecular basis of this selection is unclear, but may involve an increase in the number and/or the affinity of other, as yet unidentified, cell surface molecules. An unexpected compensatory mechanism demonstrated in this study appears to be the ability of LFA-lI-deficient CTL to utilize LFA-1 expressed on the target cell. Together, clonal selection and the novel utilization of cell surface molecules appear to be complementary mechanisms by which human T cells may compensate for significant genetic deficiencies. Further work will be necessary to elucidate the functional relationship of LFA-lI to other T cell surface molecules and to further define the role of LFA-1I in the CTL-target cell interaction.
